Correspondence | Published:

Hyperhydration is not necessary for high-dose melphalan in stem cell transplantation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Product Information. ALKERAN® ApoPharm USA Inc, 2011.

  2. 2.

    High Dose Melphalan Guideline. South West Clinical Network NHS, 2017. http://www.swscn.org.uk/wp/wp-content/uploads/2014/12/High-dose-melphlan.pdf. Accessed March 2019.

  3. 3.

    Castagna L, Crocchiolo R, Giordano L, Bramanti S, Carlo-Stella C, Sarina B, et al. High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant. Bone Marrow Transplant. 2015;50:499–504.

  4. 4.

    McElwain TJ, Hedley DW, Burton G, Clink HM, Gordon MY, Jarman M, et al. Marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high dose melphalan. Br J Cancer. 1979;40:72–80.

  5. 5.

    McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet. 1983;322:822–4.

  6. 6.

    Ardiet C, Tranchand B, Biron P, Rebattu P, Philip T. Pharmacokinetics of high-dose intravenous melphalan in children and adults with forced diuresis. Cancer Chemother Pharm. 1986;16:300–5.

  7. 7.

    Segeren CM, Sonneveld P, van der Holt B, Vellenga E, Croockewit AJ, Verhoef GEG, et al. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood. 2003;101:2144–51.

  8. 8.

    eviQ. Guidelines. www.eviq.org.au

  9. 9.

    Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney International Supplements. 2012;2:1.

Download references

Acknowledgements

We wish to acknowledge ESA International and the Leukaemia Foundation for their financial support for the presentation of this study at the European Society for Blood and Marrow Transplantation Meeting 2018.

Author information

Correspondence to Midori Nakagaki.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark
Fig. 1